Orencia Launch Anticipated By Bristol In Early 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb expects to gain approval for its rheumatoid arthritis therapy Orencia "soon" and plans to launch the biologic in early 2006, CEO Peter Dolan said during the company's third quarter sales and earnings call Oct. 28
You may also be interested in...
Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date
The rheumatoid arthritis agent is expected to be available by the end of February.
Christmas Comes Early For Bristol: Orencia Approved A Week Before User Fee Date
The rheumatoid arthritis agent is expected to be available by the end of February.
Bristol On Track For Growth In 2007 Despite Pargluva Setback
Bristol is reallocating resources toward existing products and aiming to reach growth targets through other pipeline candidates following the delay and possible termination of muraglitazar.